Also In The News:
UCLan awarded funding to help small businesses
Newton Heath to benefit from investment and improvements
Northwest businesses investigate Olympic opportunities
Burnley business park 'is flourishing'
Personal care giant invests in northwest site
Liverpool firm receives investment for internet services
Manchester University secures funding for business skills training
NWDA announces investment to help region's businesses
Northwest pharmas submit diabetes drug application
28/07/2008
Onglyza or Saxagliptin is under joint development by AstraZeneca and Bristol-Myers Squibb. The therapy is being studied in clinical trials as a once-daily therapy to determine its effectiveness and safety.
The two pharmaceutical giants have also asked the European Medicines Agency to validate a marketing authorisation application for the drug.
AstraZeneca and Bristol-Myers Squibb started working together in January 2007 to enable both companies to research, develop and commercialise investigational drugs for type-2 diabetes.
Both companies have a major presence in England's northwest.
AstraZeneca has a research and development facility in Cheshire, one of the company's biggest.
Bristol-Myers Squibb, which reported pre-tax profits of £21.3 million and a turnover of £120.5 million in 2007-08, has an 11.2 acre research and development site on the Wirral Peninsula, which investigates new medicinal compounds.
